Observation of symptomatic thromboembolic events in endoscopic retrograde cholangiopancreatography patients with interruption of antithrombotic therapies
Background and objectivesAn increasing number of patients with antithrombotic therapies are undergoing endoscopic retrograde cholangiopancreatography (ERCP). Interruption of antithrombotic therapies may be associated with a higher risk of symptomatic thromboembolic (TE) events. We aimed to investiga...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1453026/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832087105323401216 |
|---|---|
| author | Jinqing Wu Jinqing Wu Jianglong Hong Hao Ding Qiao Mei |
| author_facet | Jinqing Wu Jinqing Wu Jianglong Hong Hao Ding Qiao Mei |
| author_sort | Jinqing Wu |
| collection | DOAJ |
| description | Background and objectivesAn increasing number of patients with antithrombotic therapies are undergoing endoscopic retrograde cholangiopancreatography (ERCP). Interruption of antithrombotic therapies may be associated with a higher risk of symptomatic thromboembolic (TE) events. We aimed to investigate the risk of symptomatic TE events among patients undergoing ERCP.MethodsA retrospective cohort study on patients at risk for symptomatic TE events who had undergone ERCP from January 2016 to October 2023 was conducted. A total of 2,482 patients who had undergone ERCP were included in this study. We compared the risk of symptomatic TE events within 30 days after ERCP between the group treated with antithrombotic agent and the group not treated with antithrombotic agent using multivariate regression analysis adjusted for covariates.ResultsA total of 15 patients (0.60%, 15/2,482) developed symptomatic TE events within 30 days after ERCP. The symptomatic TE event rate in subjects on any antithrombotic drug was 1.46% with an odds ratio (OR) of 5.267 (n = 689, 95% CI 1.79–15.46, p = 0.002), compared with those not treated with antithrombotic drugs (n = 1,793). The symptomatic TE event rate in subjects on temporary interruption of antithrombotic drugs was 1.48% with an OR of 5.36 (n = 677, 95% CI 1.83–15.74, p = 0.002), compared with those not treated with antithrombotic drugs (n = 1,793). Multivariate regression analysis indicated that patients with high-risk conditions had a significantly higher risk of post-ERCP symptomatic TE events (adjusted OR 11.73, 95% CI 2.23–61.70).ConclusionInterruption of antithrombotic drugs is associated with higher post-ERCP symptomatic TE events, particularly in high-risk conditions. |
| format | Article |
| id | doaj-art-2efb7764b05b43838c7c3927b308b74b |
| institution | Kabale University |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-2efb7764b05b43838c7c3927b308b74b2025-02-06T07:09:31ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-02-011210.3389/fmed.2025.14530261453026Observation of symptomatic thromboembolic events in endoscopic retrograde cholangiopancreatography patients with interruption of antithrombotic therapiesJinqing Wu0Jinqing Wu1Jianglong Hong2Hao Ding3Qiao Mei4Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaDepartment of Gastroenterology, Fuyang People’s Hospital, Fuyang, ChinaDepartment of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaDepartment of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaDepartment of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei, ChinaBackground and objectivesAn increasing number of patients with antithrombotic therapies are undergoing endoscopic retrograde cholangiopancreatography (ERCP). Interruption of antithrombotic therapies may be associated with a higher risk of symptomatic thromboembolic (TE) events. We aimed to investigate the risk of symptomatic TE events among patients undergoing ERCP.MethodsA retrospective cohort study on patients at risk for symptomatic TE events who had undergone ERCP from January 2016 to October 2023 was conducted. A total of 2,482 patients who had undergone ERCP were included in this study. We compared the risk of symptomatic TE events within 30 days after ERCP between the group treated with antithrombotic agent and the group not treated with antithrombotic agent using multivariate regression analysis adjusted for covariates.ResultsA total of 15 patients (0.60%, 15/2,482) developed symptomatic TE events within 30 days after ERCP. The symptomatic TE event rate in subjects on any antithrombotic drug was 1.46% with an odds ratio (OR) of 5.267 (n = 689, 95% CI 1.79–15.46, p = 0.002), compared with those not treated with antithrombotic drugs (n = 1,793). The symptomatic TE event rate in subjects on temporary interruption of antithrombotic drugs was 1.48% with an OR of 5.36 (n = 677, 95% CI 1.83–15.74, p = 0.002), compared with those not treated with antithrombotic drugs (n = 1,793). Multivariate regression analysis indicated that patients with high-risk conditions had a significantly higher risk of post-ERCP symptomatic TE events (adjusted OR 11.73, 95% CI 2.23–61.70).ConclusionInterruption of antithrombotic drugs is associated with higher post-ERCP symptomatic TE events, particularly in high-risk conditions.https://www.frontiersin.org/articles/10.3389/fmed.2025.1453026/fullendoscopic retrograde cholangiopancreatographysymptomatic thromboembolic eventsbleedingantithrombotic therapieshigh-risk conditions |
| spellingShingle | Jinqing Wu Jinqing Wu Jianglong Hong Hao Ding Qiao Mei Observation of symptomatic thromboembolic events in endoscopic retrograde cholangiopancreatography patients with interruption of antithrombotic therapies Frontiers in Medicine endoscopic retrograde cholangiopancreatography symptomatic thromboembolic events bleeding antithrombotic therapies high-risk conditions |
| title | Observation of symptomatic thromboembolic events in endoscopic retrograde cholangiopancreatography patients with interruption of antithrombotic therapies |
| title_full | Observation of symptomatic thromboembolic events in endoscopic retrograde cholangiopancreatography patients with interruption of antithrombotic therapies |
| title_fullStr | Observation of symptomatic thromboembolic events in endoscopic retrograde cholangiopancreatography patients with interruption of antithrombotic therapies |
| title_full_unstemmed | Observation of symptomatic thromboembolic events in endoscopic retrograde cholangiopancreatography patients with interruption of antithrombotic therapies |
| title_short | Observation of symptomatic thromboembolic events in endoscopic retrograde cholangiopancreatography patients with interruption of antithrombotic therapies |
| title_sort | observation of symptomatic thromboembolic events in endoscopic retrograde cholangiopancreatography patients with interruption of antithrombotic therapies |
| topic | endoscopic retrograde cholangiopancreatography symptomatic thromboembolic events bleeding antithrombotic therapies high-risk conditions |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2025.1453026/full |
| work_keys_str_mv | AT jinqingwu observationofsymptomaticthromboemboliceventsinendoscopicretrogradecholangiopancreatographypatientswithinterruptionofantithrombotictherapies AT jinqingwu observationofsymptomaticthromboemboliceventsinendoscopicretrogradecholangiopancreatographypatientswithinterruptionofantithrombotictherapies AT jianglonghong observationofsymptomaticthromboemboliceventsinendoscopicretrogradecholangiopancreatographypatientswithinterruptionofantithrombotictherapies AT haoding observationofsymptomaticthromboemboliceventsinendoscopicretrogradecholangiopancreatographypatientswithinterruptionofantithrombotictherapies AT qiaomei observationofsymptomaticthromboemboliceventsinendoscopicretrogradecholangiopancreatographypatientswithinterruptionofantithrombotictherapies |